Method of administering decitabine
Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.
1. A method for administering decitabine to a patient suffering from a disease, comprising:
providing a first vessel which contains decitabine in solid form and a second vessel which contains a diluent comprising glycerin, propylene glycol, polyethylene glycol or combinations thereof, and less than 40% water in volume in the diluent;
mixing decitabine from the first vessel with the diluent from the second vessel to produce a liquid pharmaceutical composition; and
administering to the patient the pharmaceutical formulation.
2. The method of claim 1 , wherein the pharmaceutical formulation is administered orally, parenterally, topically, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery, subcutaneously, intraadiposally, intraarticularly, or intrathecally.
3. The method of claim 1 , wherein the pharmaceutical formulation is administrated intravenously.
4. The method of claim 1 , further comprising:
administering to the patient a non-decitabine therapeutic agent in combination with the pharmaceutical formulation.
5. The method of claim 4 , wherein the non-decitabine therapeutic agent is selected from the group consisting of antibiotic agents, alkylating agents, retinoids, hormonal agents, plant-derived agents, biologic agents, interleukins, interferons, cytokines, immuno-modulating agents, and monoclonal antibodies.
6. The method of claim 1 , wherein the disease is selected from the group consisting of hematological disorders, benign tumor and cancer.
7. The method of claim 1 , wherein the step of administering includes:
diluting the pharmaceutical formulation with an aqueous solution; and
administering the resulting diluted pharmaceutical formulation;
wherein the dilution is performed 10 hr, 2 hr, 1 hr, 30 min, 10 min, 5 min or less before administration.
8. The method of claim 1 , wherein the step of administering includes:
admixing aliquots of the pharmaceutical formulation with an aqueous solution; and
infusing the resulting solution into the patient's body.
9. The method of claim 8 , wherein a Y connector is used to admix the aliquots of the pharmaceutical formulation.
10. The method of claim 8 , wherein infusion is performed over a period at least 3 hours.
11. The method of claim 8 , wherein infusion is performed over a period at least 5 hours.